NCT01938443View on ClinicalTrials.gov

A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 18, 2013

Primary Completion Date

June 23, 2016

Study Completion Date

June 23, 2016

Conditions
CancerNeoplasms
Interventions
DRUG

GSK2256098

GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.

DRUG

Trametinib

Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.

Trial Locations (4)

94805

GSK Investigational Site, Villejuif

W12 0HS

GSK Investigational Site, London

W1G 6AD

GSK Investigational Site, London

NE7 7DN

GSK Investigational Site, Newcastle upon Tyne

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01938443 - A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter